TOP > 外国特許検索 > HEPATITIS B VACCINE

HEPATITIS B VACCINE NEW

外国特許コード F190009745
整理番号 (S2017-0862-N0)
掲載日 2019年5月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP027412
国際公開番号 WO 2019013361
国際出願日 平成30年7月13日(2018.7.13)
国際公開日 平成31年1月17日(2019.1.17)
優先権データ
  • 特願2017-138047 (2017.7.14) JP
発明の名称 (英語) HEPATITIS B VACCINE NEW
発明の概要(英語) This hepatitis B vaccine includes surface antigen particles formed in which only L-proteins of the hepatitis B virus, or mutants of said L-proteins, collect on the lipid membrane.
従来技術、競合技術の概要(英語) BACKGROUND ART
(HBV) hepatitis B virus surface antigen is, L antigen (Pre-S1, Pre-S2 and S formed from a region), the antigen M (Pre-S2 and S formed from a region) and the antigen S (S is formed only from) there are two types of 3 (each of these antigens, antigen HBs-L, an antigen HBs-M, also referred to as antigen HBs-S.). Hepatitis B vaccine is, the antigen S are mainly used, in part, M antigens have been used. HBV surface antigens of the protein that functions as, Pre-S1 region recognizes human hepatocytes HBV virus, is coupled to the sensor. Therefore, the function of the Pre-S1 region against Hepatitis B vaccine is neutralizing antibodies as well as promising, HBV spread of the virus body to prevent important as a vaccine treatment means.
L a gene encoding a protein (referred to as L antigen gene) is, a single translation start site and 3 have a common termination codon. Therefore L CHO cell antigen gene is expressed in a cell of the animal, L, M and S of the two proteins 3 are formed. The 3 one protein in the lipid particles can be presented to one of L, M and S protein antigen is mixed with the particles will be formed. Under such circumstances, one of the 3 antigen is an antigen L, M and S using a mixture of an antigen and antigen vaccine has been known (for example, a prophylactic vaccine is commercially available (VBI Vaccines inc. Israel) Sci-B-VacTM. In addition, a mixture of 3 types of treatment of hepatitis B antigen used as a vaccine may be considered to be (HBV vaccine and a manufacturing method thereof: JP-2010-516807). However, these L of the antigen is an antigen, antigen and antigen S M is a mixture of, by using L antigen vaccine development is not known.
However, the duration (HBV) hepatitis B viral infection in the world the user is expected to exist about 4 million and, in japan HBV infection rates up to 1.5%. In japan, HBV mother infant for contamination prevention, screening of blood transfusion, administration of the vaccine to the high risk group (selective vaccination) has the effect of various precautions such as successful, the user tends to decrease the number of HBV infection. On the other hand, these precautions are not subject to many people, not against HBV, in a state vulnerable for HBV, even by the current number found in acute hepatitis B type horizontal primary infection, fulminant hepatitis can be a patient. These horizontal for the prevention of infection, there is a demand for universal vaccination in japan HBV is started from.
As described above, HBV HBs-L antigen on the surface of a viral particle, HBs-M antigens, antigen HBs-S 3 different types of proteins (Fig. 1) is present. Japan 2 HBV in a prophylactic vaccine may be used is type, both of which antigen HBs-S, any person may have about 10% in the production of a vaccine HBs antibody was not observed (non-responders to vaccine HB), the benefits of vaccination HBV not be obtained. Therefore, the eradication of HBV infection is horizontal, a small non-response of HBV vaccine, a vaccine is required more powerful. The hepatitis B antigen using HBs-S immune therapy is attempted, sufficient therapeutic effect is not obtained, a more powerful immune therapy is obtained.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
  • EHIME UNIVERSITY
  • Kagoshima University
  • BEACLE INC.
  • 発明者(英語)
  • KOHARA Michinori
  • SANADA Takahiro
  • HIASA Yoichi
  • KOHARA Koko
  • GOH Yasumasa
  • ODA Yasunori
国際特許分類(IPC)
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close